VIATRIS INC. Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax
VIATRIS INC. (VTRS) reported Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax of -$61.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax · last filed 2026-08-06
- VIATRIS INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax for the quarter ending 2026-06-30 was -$61.00M, a 112.03% decline year-over-year.
- VIATRIS INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax for the quarter ending 2026-03-31 was -$133.60M, a 126.78% decline year-over-year.
- VIATRIS INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax for the quarter ending 2025-12-31 was -$29.20M.
- VIATRIS INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax for the quarter ending 2025-09-30 was -$74.00M, a 114.51% decline year-over-year.
- VIATRIS INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax for fiscal 2025 was $902.60M.
- VIATRIS INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax for fiscal 2024 was -$744.10M, a 634.55% decline from fiscal 2023.
- VIATRIS INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax for fiscal 2023 was $139.20M.
- VIATRIS INC. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax for fiscal 2020 was $1.21B.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax 3 month | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax 6 month | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax 9 month | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$61.00M 10-Q · filed 2026-08-06 | -$194.60M 10-Q · filed 2026-08-06 | -$223.80M derived: sum of 3 quarters · filed 2026-08-06 | -$297.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$133.60M 10-Q · filed 2026-05-07 | -$162.80M derived: sum of 2 quarters · filed 2026-05-07 | -$236.80M derived: sum of 3 quarters · filed 2026-05-07 | $270.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$29.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$103.20M derived: sum of 2 quarters · filed 2026-02-26 | $403.80M derived: sum of 3 quarters · filed 2026-08-06 | $902.60M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$74.00M 10-Q · filed 2025-11-06 | $433.00M derived: sum of 2 quarters · filed 2026-08-06 | $931.80M 10-Q · filed 2025-11-06 | $109.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $507.00M 10-Q · filed 2026-08-06 | $1.01B 10-Q · filed 2026-08-06 | $183.90M derived: sum of 3 quarters · filed 2026-08-06 | $693.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $498.80M 10-Q · filed 2026-05-07 | -$323.10M derived: sum of 2 quarters · filed 2026-05-07 | $186.90M derived: sum of 3 quarters · filed 2026-05-07 | $97.20M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$821.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$311.90M derived: sum of 2 quarters · filed 2026-02-26 | -$401.60M derived: sum of 3 quarters · filed 2026-02-26 | -$744.10M 10-K · filed 2026-02-26 |
| 2024-09-30 | $510.00M 10-Q · filed 2025-11-06 | $420.30M derived: sum of 2 quarters · filed 2025-11-06 | $77.80M 10-Q · filed 2025-11-06 | $776.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$89.70M 10-Q · filed 2025-08-07 | -$432.20M 10-Q · filed 2025-08-07 | $266.60M derived: sum of 3 quarters · filed 2026-02-26 | -$84.20M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$342.50M 10-Q · filed 2025-05-08 | $356.30M derived: sum of 2 quarters · filed 2026-02-26 | $5.50M derived: sum of 3 quarters · filed 2026-02-26 | -$248.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $698.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $348.00M derived: sum of 2 quarters · filed 2026-02-26 | $93.90M derived: sum of 3 quarters · filed 2026-02-26 | $139.20M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$350.80M 10-Q · filed 2024-11-07 | -$604.90M derived: sum of 2 quarters · filed 2024-11-07 | -$559.60M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$254.10M 10-Q · filed 2024-08-08 | -$208.80M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $45.30M 10-Q · filed 2024-05-09 | |||
| 2022-09-30 | -$1.16B 10-Q · filed 2023-11-08 | -$2.31B derived: sum of 2 quarters · filed 2023-11-08 | -$2.78B 10-Q · filed 2023-11-08 | |
| 2022-06-30 | -$1.15B 10-Q · filed 2023-08-07 | -$1.62B 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | -$469.20M 10-Q · filed 2023-05-08 | |||
| 2021-09-30 | -$407.40M 10-Q · filed 2022-11-07 | -$246.70M derived: sum of 2 quarters · filed 2022-11-07 | -$967.90M 10-Q · filed 2022-11-07 | -$238.00M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $160.70M 10-Q · filed 2022-08-08 | -$560.50M 10-Q · filed 2022-08-08 | $169.40M derived: sum of 3 quarters · filed 2022-08-08 | $857.10M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$721.20M 10-Q · filed 2022-05-09 | $8.70M derived: sum of 2 quarters · filed 2022-05-09 | $696.40M derived: sum of 3 quarters · filed 2022-05-09 | $1.15B derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $729.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.42B derived: sum of 2 quarters · filed 2021-11-08 | $1.87B derived: sum of 3 quarters · filed 2021-11-08 | $1.21B 10-K · filed 2021-03-01 |
| 2020-09-30 | $687.70M 10-Q · filed 2021-11-08 | $1.14B derived: sum of 2 quarters · filed 2021-11-08 | $483.10M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $452.00M 10-Q · filed 2021-08-09 | -$204.60M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$656.60M 10-Q · filed 2021-05-10 | |||
| 2018-12-31 | -$1.13B 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |